ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $18,485,000 | +36.0% | 107,408 | -0.8% | 0.01% | +40.0% |
| Q2 2021 | $13,591,000 | -10.5% | 108,307 | -3.3% | 0.01% | -16.7% |
| Q1 2021 | $15,188,000 | +0.6% | 111,995 | -5.1% | 0.01% | 0.0% |
| Q4 2020 | $15,104,000 | +14.0% | 118,053 | +0.2% | 0.01% | 0.0% |
| Q3 2020 | $13,254,000 | +35.2% | 117,780 | +14.5% | 0.01% | +20.0% |
| Q2 2020 | $9,803,000 | +8.8% | 102,892 | +2.6% | 0.01% | -9.1% |
| Q1 2020 | $9,012,000 | +66.1% | 100,282 | -2.0% | 0.01% | +120.0% |
| Q4 2019 | $5,426,000 | +64.8% | 102,332 | +22.8% | 0.01% | +66.7% |
| Q3 2019 | $3,293,000 | +28.7% | 83,334 | +33.8% | 0.00% | 0.0% |
| Q2 2019 | $2,558,000 | -10.8% | 62,262 | +1.1% | 0.00% | -25.0% |
| Q1 2019 | $2,869,000 | +5.4% | 61,614 | -1.4% | 0.00% | 0.0% |
| Q4 2018 | $2,722,000 | -30.1% | 62,514 | -8.1% | 0.00% | -20.0% |
| Q3 2018 | $3,892,000 | +10.3% | 68,014 | -6.5% | 0.01% | 0.0% |
| Q2 2018 | $3,528,000 | +323.5% | 72,714 | +241.4% | 0.01% | +400.0% |
| Q1 2018 | $833,000 | -11.9% | 21,300 | -4.5% | 0.00% | 0.0% |
| Q4 2017 | $946,000 | +21.3% | 22,300 | +6.7% | 0.00% | 0.0% |
| Q3 2017 | $780,000 | +22.8% | 20,900 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $635,000 | +14.8% | 20,900 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $553,000 | -1.1% | 20,900 | -4.6% | 0.00% | 0.0% |
| Q4 2016 | $559,000 | -30.1% | 21,900 | -0.9% | 0.00% | 0.0% |
| Q3 2016 | $800,000 | -1.1% | 22,100 | -7.1% | 0.00% | 0.0% |
| Q2 2016 | $809,000 | +25.6% | 23,800 | -2.5% | 0.00% | 0.0% |
| Q1 2016 | $644,000 | -49.0% | 24,400 | -5.8% | 0.00% | -50.0% |
| Q4 2015 | $1,263,000 | +95.8% | 25,900 | 0.0% | 0.00% | +100.0% |
| Q3 2015 | $645,000 | -21.2% | 25,900 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $819,000 | -42.6% | 25,900 | -26.0% | 0.00% | -50.0% |
| Q1 2015 | $1,426,000 | 0.0% | 35,002 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,426,000 | – | 35,002 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |